Roslin Institute

Oxitec Launches New Scotland R&D Hub to Spearhead a New Global Fight Against Invasive Cattle Ticks

Retrieved on: 
Tuesday, February 13, 2024
Parasitism, Livestock, Roslin Institute, Farmer, Cattle, Bangladesh Technical Education Board, Babesiosis, University, Pesticide, Anaplasmosis, Science, Partnership, Agriculture

Oxitec is collaborating with the globally respected livestock research organisation, the Roslin Institute, located outside of Edinburgh, Scotland.

Key Points: 
  • Oxitec is collaborating with the globally respected livestock research organisation, the Roslin Institute, located outside of Edinburgh, Scotland.
  • R. microplus spreads deadly cattle diseases, causes billions of dollars of losses to farmers across the world, and is widely resistant to chemical pesticides.
  • It is spreading at an alarming rate through many African countries and is a growing threat to farmer livelihoods worldwide.
  • Oxitec is expanding its team of in-house specialists in the new Scotland hub, dedicated to developing the world's first Friendly™ R. microplus solution.

Oxitec Launches New Scotland R&D Hub to Spearhead a New Global Fight Against Invasive Cattle Ticks

Retrieved on: 
Tuesday, February 13, 2024
Parasitism, Livestock, Roslin Institute, Farmer, Cattle, Bangladesh Technical Education Board, Babesiosis, University, Pesticide, Anaplasmosis, Science, Partnership, Agriculture

Oxitec is collaborating with the globally respected livestock research organisation, the Roslin Institute, located outside of Edinburgh, Scotland.

Key Points: 
  • Oxitec is collaborating with the globally respected livestock research organisation, the Roslin Institute, located outside of Edinburgh, Scotland.
  • R. microplus spreads deadly cattle diseases, causes billions of dollars of losses to farmers across the world, and is widely resistant to chemical pesticides.
  • It is spreading at an alarming rate through many African countries and is a growing threat to farmer livelihoods worldwide.
  • Oxitec is expanding its team of in-house specialists in the new Scotland hub, dedicated to developing the world's first Friendly™ R. microplus solution.

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

Retrieved on: 
Tuesday, November 28, 2023
Policy, Sickle cell disease, Gene editing, Health care, Nobel, ARD International Music Competition, CRISPR, Vertex Pharmaceuticals, CGMP, MHRA, Heart, Roslin Institute, Patient, NHS, Medicine, Bangladesh Technical Education Board, Pharmaceutical industry

RoslinCT has a rich history of innovation in stem cell technology, dating back to its genesis at the Roslin Institute in Edinburgh.

Key Points: 
  • RoslinCT has a rich history of innovation in stem cell technology, dating back to its genesis at the Roslin Institute in Edinburgh.
  • Exa-cel is a new treatment for sickle cell disease and transfusion-dependent beta thalassemia, authorised by the UK Medicines and Healthcare products Regulatory Agency (‘MHRA’) on 15 November 2023.
  • The MHRA granted RoslinCT a Manufacturer’s Authorisation License (‘MIA’) for commercial manufacturing of cell therapy products in March 2023.
  • We also already have in place the NHS innovative medicine fund as an explicit policy route to enable rapid adoption of innovation.

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

Retrieved on: 
Tuesday, November 28, 2023
Policy, Sickle cell disease, Gene editing, Health care, Nobel, ARD International Music Competition, CRISPR, Vertex Pharmaceuticals, CGMP, MHRA, Heart, Roslin Institute, Patient, NHS, Medicine, Bangladesh Technical Education Board, Pharmaceutical industry

RoslinCT has a rich history of innovation in stem cell technology, dating back to its genesis at the Roslin Institute in Edinburgh.

Key Points: 
  • RoslinCT has a rich history of innovation in stem cell technology, dating back to its genesis at the Roslin Institute in Edinburgh.
  • Exa-cel is a new treatment for sickle cell disease and transfusion-dependent beta thalassemia, authorised by the UK Medicines and Healthcare products Regulatory Agency (‘MHRA’) on 15 November 2023.
  • The MHRA granted RoslinCT a Manufacturer’s Authorisation License (‘MIA’) for commercial manufacturing of cell therapy products in March 2023.
  • We also already have in place the NHS innovative medicine fund as an explicit policy route to enable rapid adoption of innovation.

THE BUSINESS OF SAVING LIVES HEADS TO THE HIGHLANDS

Retrieved on: 
Thursday, October 5, 2023
Business, Roslin Institute, Compassion, Organization, Empathy, Battersea Dogs & Cats Home, Society for the Protection of Animals Abroad, Maggie, Polish American Association, Social media, Helen Woodward Animal Center, UAnimals, Demographics, Bangladesh Technical Education Board, International, Moon, School, University of Edinburgh, Rancho Santa Fe, California, University, Marketing, Medicine, City, SCAS, Organic, Travel, Pet, Conference, Animal

RANCHO SANTA FE, Calif., Oct. 5, 2023 /PRNewswire/ -- At this very moment, Helen Woodward Animal Center professionals are on a journey of over 5,000 miles, flying to meet with animal welfare advocates in Edinburgh, Scotland. Through The Business of Saving Lives, the Center has demonstrated its dedication to saving the lives of orphan pets, not only within its San Diego-based facility, but within shelters and rescues across the globe. Today, Helen Woodward Animal Center leaders are on their way to conference with Scottish shelter groups working towards the humane treatment of animals on the other side of the world. Scotland-based humane education charity Fostering Compassion is joining forces with Helen Woodward Animal Center to host its Compassion Allways Conference as part of the Royal (Dick) School of Veterinary Studies Bicentenary Celebrations. The conference will take place over the weekend of the 7th and 8th October 2023 at the Easter Bush Campus.

Key Points: 
  • Through The Business of Saving Lives, the Center has demonstrated its dedication to saving the lives of orphan pets, not only within its San Diego-based facility, but within shelters and rescues across the globe.
  • The conference will take place over the weekend of the 7th and 8th October 2023 at the Easter Bush Campus.
  • The Business of Saving Lives began at Helen Woodward Animal Center in 2002 as quarterly workshops, taught by Center management team members on the Rancho Santa Fe, California grounds.
  • To become an agent of change for animal welfare, apply for a FREE The Business of Saving Lives workshop in your own town.

RoslinCT and Lykan Bioscience Announce Integration to Establish Global Advanced Cell and Gene Therapy CDMO Service Offerings

Retrieved on: 
Monday, June 5, 2023
CRISPR, Sheep, University, Center for Cell and Gene Therapy, Gene, IPSC, Advanced Cell Therapeutics, Gene editing, History, Science, Organization, Roslin Institute, CGMP, Gene therapy, Disease, Fine chemical, Cell, Atlantic Ocean

EDINBURGH, U.K. and BOSTON, U.S., June 5, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.

Key Points: 
  • EDINBURGH, U.K. and BOSTON, U.S., June 5, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.
  • The integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell and Gene Therapy CDMO market.
  • These services will empower Cell and Gene Therapy developers to advance their products through clinical trials and bring them to market.
  • Our proven experience in Cell and Gene Therapy, coupled with our combined global capabilities, will provide our partners with superior service and support as we continue to advance life-saving therapies worldwide."

RoslinCT and Lykan Bioscience Announce Integration to Establish Global Advanced Cell and Gene Therapy CDMO Service Offerings

Retrieved on: 
Monday, June 5, 2023
CRISPR, Sheep, University, Center for Cell and Gene Therapy, Gene, IPSC, Advanced Cell Therapeutics, Gene editing, History, Science, Organization, Roslin Institute, CGMP, Gene therapy, Disease, Fine chemical, Cell, Atlantic Ocean

EDINBURGH, U.K. and BOSTON, U.S., June 5, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.

Key Points: 
  • EDINBURGH, U.K. and BOSTON, U.S., June 5, 2023 /PRNewswire/ -- RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, announce their integration, creating a unified business that will operate under the RoslinCT brand.
  • The integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell and Gene Therapy CDMO market.
  • These services will empower Cell and Gene Therapy developers to advance their products through clinical trials and bring them to market.
  • Our proven experience in Cell and Gene Therapy, coupled with our combined global capabilities, will provide our partners with superior service and support as we continue to advance life-saving therapies worldwide."

Oxitec Launches New Technology Program to Develop a Friendly™ Solution for the World's Most Damaging Cattle Tick

Retrieved on: 
Wednesday, May 24, 2023
Bangladesh Technical Education Board, Genetics, Babesiosis, Farmer, Livestock, Research, Bill & Melinda Gates Foundation, OXFORD, Roslin Institute, Pesticide, Cattle, Oxitec, Biology, Bill, Environment, Agriculture, Rhipicephalus

Oxitec's Friendly™ Cattle Tick Program team has conducted a successful feasibility phase, finding that development and future application of a Friendly™ solution for the world's most damaging blood-feeding cattle pest is highly achievable and anticipated to deliver future benefits to the world's cattle farmers.

Key Points: 
  • Oxitec's Friendly™ Cattle Tick Program team has conducted a successful feasibility phase, finding that development and future application of a Friendly™ solution for the world's most damaging blood-feeding cattle pest is highly achievable and anticipated to deliver future benefits to the world's cattle farmers.
  • The R. microplus tick blood-feeds on cattle, causing major losses in productivity and animal death by spreading deadly diseases such as babesiosis.
  • The Rhipicephalus microplus tick is a dangerous pest of cattle that threatens livelihoods across the world, and it's still spreading.
  • Kelly Matzen, Oxitec's Chief Technology Officer, added, "We're looking forward to starting work on development of the world's most sustainable tick management solution.

Oxitec Launches New Technology Program to Develop a Friendly™ Solution for the World's Most Damaging Cattle Tick

Retrieved on: 
Wednesday, May 24, 2023
Bangladesh Technical Education Board, Genetics, Babesiosis, Farmer, Livestock, Research, Bill & Melinda Gates Foundation, OXFORD, Roslin Institute, Pesticide, Cattle, Oxitec, Biology, Bill, Environment, Agriculture, Rhipicephalus

Oxitec's Friendly™ Cattle Tick Program team has conducted a successful feasibility phase, finding that development and future application of a Friendly™ solution for the world's most damaging blood-feeding cattle pest is highly achievable and anticipated to deliver future benefits to the world's cattle farmers.

Key Points: 
  • Oxitec's Friendly™ Cattle Tick Program team has conducted a successful feasibility phase, finding that development and future application of a Friendly™ solution for the world's most damaging blood-feeding cattle pest is highly achievable and anticipated to deliver future benefits to the world's cattle farmers.
  • The R. microplus tick blood-feeds on cattle, causing major losses in productivity and animal death by spreading deadly diseases such as babesiosis.
  • The Rhipicephalus microplus tick is a dangerous pest of cattle that threatens livelihoods across the world, and it's still spreading.
  • Kelly Matzen, Oxitec's Chief Technology Officer, added, "We're looking forward to starting work on development of the world's most sustainable tick management solution.

Future Planet Capital backs Roslin Tech’s momentum with further investment

Retrieved on: 
Friday, November 4, 2022
Finance, Fintech, Consulting, Professional Services, Biotechnology, Food, Beverage, Health, Retail, Organic Food, Other Professional Services, Leadership, Protein, Animal, Science, Growth, Education, MBI, Environment, Breeding, Roslin Institute, Monaco, Cell, COP, Investment, University, Future, Prince, Veterinary medicine, CEO, Meat, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, The Blue Economy, Health, FPC, Climate change, Technology, Blue Ocean Strategy, Blue, Bangladesh Technical Education Board, Prince Albert II of Monaco Foundation, Blue economy, Development, Renewable energy

We are very pleased that Future Planet Capital continues to support us both financially and strategically.

Key Points: 
  • We are very pleased that Future Planet Capital continues to support us both financially and strategically.
  • Future Planet is the impact-led venture capital firm built to back growth companies from the world's top universities and research ecosystems.
  • Future Planet Capitals goal is to profitably solve the world's greatest challenges in climate change, education, health, sustainable growth & security.
  • Future Planet Challenge Response II (CRII) is a thematic basket investing in top companies directly combating the effects of climate change.